Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.41 |
| ▸ | SYK | P43405 | 10/20 | 0.40 |
| ▸ | CD63 | P08962 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14878009 | 0.88 | AURKA (0.41) | AURKASYKCD63BTK | |
| SCHEMBL13531793 | 0.80 | BTK (0.46) | AURKASYKBTK | |
| SCHEMBL13531807 | 0.79 | SYK (0.39) | AURKASYKCD63BTK | |
| SCHEMBL14878012 | 0.73 | BTK (0.37) | SYKBTK | |
| SCHEMBL13531792 | 0.73 | BTK (0.44) | AURKASYKBTK | |
| SCHEMBL12637969 | 0.69 | AURKA (0.50) | AURKASYKCD63 | |
| SCHEMBL13531785 | 0.69 | HTR2C (0.47) | AURKABTK | |
| SCHEMBL1069035 | 0.67 | AURKA (0.50) | AURKASYKCD63 | |
| SCHEMBL5277013 | 0.66 | AURKA (0.47) | AURKASYKCD63 | |
| SCHEMBL20319061 | 0.66 | NUDT1 (0.42) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426409-B2 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | BTK, LCK, LYN | AURKA 1148/4885SYK 5/4885CD63 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.